130 related articles for article (PubMed ID: 22687971)
41. Inflammatory Cells in Atypical Eruption of Lymphocyte Recovery Carry the Same Mutations as Neoplastic Myeloid Cells.
Prieto-Torres L; Chamizo C; Salgado RN; Atance M; Soto C; Alonso Domínguez JM; Arquero T; Piris MA; Requena L; Rodriguez-Pinilla SM
Am J Dermatopathol; 2020 May; 42(5):360-363. PubMed ID: 31592861
[TBL] [Abstract][Full Text] [Related]
42. Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.
Tabei Y; Kobayashi K; Saito K; Shimizu S; Suzuki K; Sasaki N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2021 Jan; 51(1):45-53. PubMed ID: 32888020
[TBL] [Abstract][Full Text] [Related]
43. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
[TBL] [Abstract][Full Text] [Related]
44. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.
Patnaik MM; Lasho TL; Finke CM; Gangat N; Caramazza D; Holtan SG; Pardanani A; Knudson RA; Ketterling RP; Chen D; Hoyer JD; Hanson CA; Tefferi A
Leukemia; 2010 Jul; 24(7):1283-9. PubMed ID: 20485371
[TBL] [Abstract][Full Text] [Related]
45. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.
Duncan CG; Barwick BG; Jin G; Rago C; Kapoor-Vazirani P; Powell DR; Chi JT; Bigner DD; Vertino PM; Yan H
Genome Res; 2012 Dec; 22(12):2339-55. PubMed ID: 22899282
[TBL] [Abstract][Full Text] [Related]
46. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
[TBL] [Abstract][Full Text] [Related]
47. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
Harding JJ; Lowery MA; Shih AH; Schvartzman JM; Hou S; Famulare C; Patel M; Roshal M; Do RK; Zehir A; You D; Selcuklu SD; Viale A; Tallman MS; Hyman DM; Reznik E; Finley LWS; Papaemmanuil E; Tosolini A; Frattini MG; MacBeth KJ; Liu G; Fan B; Choe S; Wu B; Janjigian YY; Mellinghoff IK; Diaz LA; Levine RL; Abou-Alfa GK; Stein EM; Intlekofer AM
Cancer Discov; 2018 Dec; 8(12):1540-1547. PubMed ID: 30355724
[TBL] [Abstract][Full Text] [Related]
48. Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
Whitehall VL; Dumenil TD; McKeone DM; Bond CE; Bettington ML; Buttenshaw RL; Bowdler L; Montgomery GW; Wockner LF; Leggett BA
Epigenetics; 2014 Nov; 9(11):1454-60. PubMed ID: 25496513
[TBL] [Abstract][Full Text] [Related]
49. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
50. A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Drusbosky LM; Singh NK; Hawkins KE; Salan C; Turcotte M; Wise EA; Meacham A; Vijay V; Anderson GG; Kim CC; Radhakrishnan S; Ullal Y; Talawdekar A; Sikora H; Nair P; Khanna-Gupta A; Abbasi T; Vali S; Guha S; Farhadfar N; Murthy HS; Horn BN; Leather HL; Castillo P; Tucker C; Cline C; Pettiford L; Lamba JK; Moreb JS; Brown RA; Norkin M; Hiemenz JW; Hsu JW; Slayton WB; Wingard JR; Cogle CR
Blood Adv; 2019 Jun; 3(12):1837-1847. PubMed ID: 31208955
[TBL] [Abstract][Full Text] [Related]
51. Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers.
Bledea R; Vasudevaraja V; Patel S; Stafford J; Serrano J; Esposito G; Tredwin LM; Goodman N; Kloetgen A; Golfinos JG; Zagzag D; Weigelt B; Iafrate AJ; Sulman EP; Chi AS; Dogan S; Reis-Filho JS; Chiang S; Placantonakis D; Tsirigos A; Snuderl M
Sci Rep; 2019 Nov; 9(1):16830. PubMed ID: 31727977
[TBL] [Abstract][Full Text] [Related]
52. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
53. IDH1, Histone Methylation, and So Forth.
Penard-Lacronique V; Bernard OA
Cancer Cell; 2016 Aug; 30(2):192-194. PubMed ID: 27505668
[TBL] [Abstract][Full Text] [Related]
54. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Stein EM; Fathi AT; DiNardo CD; Pollyea DA; Roboz GJ; Collins R; Sekeres MA; Stone RM; Attar EC; Frattini MG; Tosolini A; Xu Q; See WL; MacBeth KJ; de Botton S; Tallman MS; Kantarjian HM
Lancet Haematol; 2020 Apr; 7(4):e309-e319. PubMed ID: 32145771
[TBL] [Abstract][Full Text] [Related]
55. Glioblastomas with IDH1/2 mutations have a short clinical history and have a favorable clinical outcome.
Ohno M; Narita Y; Miyakita Y; Matsushita Y; Arita H; Yonezawa M; Yoshida A; Fukushima S; Takami H; Ichimura K; Shibui S
Jpn J Clin Oncol; 2016 Jan; 46(1):31-9. PubMed ID: 26603354
[TBL] [Abstract][Full Text] [Related]
56. [Genome-wide analysis of AML and MDS].
Ogawa S
Nihon Rinsho; 2012 Apr; 70 Suppl 2():113-8. PubMed ID: 23133938
[No Abstract] [Full Text] [Related]
57. Association Between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing.
Khurana S; Sluzevich JC; He R; Reimer DK; Kharfan-Dabaja MA; Foran JM; Jiang L
JAMA Dermatol; 2020 Jul; 156(7):817-819. PubMed ID: 32374348
[No Abstract] [Full Text] [Related]
58. IDH1/2 Mutation and MGMT Promoter Methylation - the Relevant Survival Predictors in Czech Patients with Brain Gliomas.
Kramář F; Minárik M; Benešová L; Halková T; Netuka D; Bradáč O; Beneš V
Folia Biol (Praha); 2016; 62(5):194-202. PubMed ID: 27978414
[TBL] [Abstract][Full Text] [Related]
59. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
[TBL] [Abstract][Full Text] [Related]
60. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
